1.Alzheimer Society of Canada. Rising tide: the impact of dementia on Canadian society executive summary; 2010.
2.Hogan, DB, Patterson, C.Progress in clinical neurosciences: Treatment of Alzheimer's disease and other dementias-review and comparison of the cholinesterase inhibitors. Can J Neurol Sci. 2002;29:306–14.
3.Amuah, JE, Hogan, DB, Eliasziw, M, et al.Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease. Pharmacoepidemiol Drug Saf. 2010;19:670–9.
4.Elliot (b). Special tabulation by Sask trends Monitor (2012) from Statistics Canada 2011 data. Sask trends Monitor. Regina, SK. Available from: http://www.sasktrends.ca.
5.Elliot (a). The age distribution of the Saskatchewan population. Sask Trends Monitor. May 2012;24:2-10.
6.Morgan, DG, Crossley, M, Kirk, A, et al.Improving access to dementia care: development and evaluation of a rural and remote memory clinic. Aging Ment Health. 2009;13:17–30.
7.Morgan, DG, Crossley, M, Kirk, A, et al.Evaluation of telehealth for preclinic assessment and follow-up in an interprofessional rural and remote memory clinic. J Appl Gerontol. 2011;30:304–31.
8.Lacny, C, Kirk, A, Morgan, DG, Karunanayake, C.Does day length affect cognitive performance in memory clinic patients? Can J Neurol Sci. 2011;38:461–4.
9.Steve, T, Kirk, A, Crossley, M, et al.Medication use in patients presenting to a rural and remote memory clinic. Can J Neurol Sci. 2008;35:669–71.
10.Umegaki, H, Itoh, A, Suzuki, Y, Nabeshima, T.Discontinuation of donepezil for the treatment of Alzheimer's disease in geriatric practice. Int Psychogeriatr. 2008;20:800–6.
11.Pfeffer, R, Kurosaki, T, Harrah, C, Chance, J, Filos, S.Measurement of functional activities in older adults in the community. J Gerontol. 1982;37:323–9.
12.Cummings, J, Mega, M, Gray, K, Rosenberg-Thompson, S, Carusi, DA, Gornbein, J.The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994; 44:2308–14.
13.Bucks, RS, Ashworth, DL, Wilcock, GK, Siegfried, K.Assessment of activities of daily living in dementia: development of the Bristol activities of daily living scale. Age Ageing. 1996;25:113–20.
14.Logsdon, RG, Gibbons, LE, McCurry, SM, Teri, L.Quality of life in Alzheimer's disease: patient and caregiver reports. J Ment Health Aging. 1999;5:21–32.
15.Radloff, LS.The CES-D Scale: a self-report depression scale for research in the general population. Appl Psych Meas. 1977;1:385–401.
16.Lawton, MP, Brody, EM.Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;3:179–86.
17.Squire, Zouzounis. Self-ratings of memory dysfunction: different findings in depression and amnesia. JCEN. 1988;10:727–38.
18.Abughosh, SM, Kogut, SJ.Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program. Patient Prefer Adher. 2008;2:79–85.
19.Herrmann, N, Binder, C, Dalziel, W, Smyth, S, Camacho, F.Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study. Drugs Aging. 2009;26:403–7.
20.Kroger, E, Van Marum, R, Souverein, P, Egberts, T.Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: a retrospective cohort study. Drugs Aging. 2010;27:663–75.
21.Farlow, M, Veloso, F, Moline, M, et al.Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. BMC Neurol. 2011;25:57.
22.Massoud, F, Desmarais, JE, Gauthier, S.Switching cholinesterase inhibitors in older adults with dementia. Int Psychogeriatr. 2011;23:372–8.
23.Herrman, N, Black, SE, Li, A, Lanctot, KL.Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts. Int Psychogeriatr. 2011;23:539–45.
24.Pariente, A, Pinet, M, Moride, Y, Merliere, Y, Moore, N, Fourrier-Reglat, A.Factors associated with persistence of cholinesterase inhibitor treatments in the elderly. Pharmacoepidemiol Drug Saf. 2010;19:680–6.